Biotechnology company Beacon Therapeutics has raised over $75 million to advance treatments for ocular diseases.  The funding was raised in an oversubscribed Series C financing round, led by Life Sciences at Goldman Sachs Alternatives and with participation from the Retinal Degeneration Fund (RD Fund), the venture arm of Foundation Fighting Blindness.  The funds will allow Beacon […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!